Gerold Meinhardt, MD, global clinical leader at Bayer Pharmaceuticals, discusses the impact of the RESORCE trial in hepatocellular carcinoma (HCC).

Regorafenib (Stivarga), was recently approved by the FDA for use in patients with HCC that have progressed on Sorafenib (Nexavar). This approval was based on the findings of the phase III RESORCE trial, which showed a significant improvement in survival with a manageable safety profile.

Meinhardt says that this trial provides hope for new therapies in a disease that is historically difficult to treat.

Videos

Gerold Meinhardt, MD, global clinical leader at Bayer Pharmaceuticals, discusses the impact of the RESORCE trial in hepatocellular carcinoma.

Gerold Meinhardt, MD

Articles

Dr. Meinhardt on the Impact of the RESORCE Study in HCC